The Neuroscience of Depression: Features, Diagnosis and Treatment, is a comprehensive reference to the diagnosis and treatment of depression. This book provides readers with the mechanisms of depression reflecting on the interplay between depression and the biological and psychosocial processes. A detailed introduction to various episodes of depression, from PTSD to post-partum depression is provided, followed by a thorough discussion on biomarkers in depression and how to diagnose depression including the Hamilton Depression Rating scale. This book also includes three full sections on treatment options for depression, including pharmacological, behavioral and other novel regimes. The Neuroscience of Depression: Features, Diagnosis and Treatment is the only resource for researchers and practitioners studying, diagnosis and treating of depression.
1. Cover image - p. page_i 2. Title page - p. page_i 3. Table of Contents - p. page_i 4. Copyright - p. page_iv 5. Contributors - p. page_xix 6. Foreword - p. page_xxv 7. Preface - p. page_xxvii 8. Part I: Depression: Introductory chapters - p. page_xxvii 9. Chapter 1: Clinical staging in depression - p. page_3 10. Chapter 2: Neurodevelopmental theory of depression - p. page_13 11. Chapter 3: Depression after pregnancy - p. page_21 12. Chapter 4: Modeling maternal depression during pregnancy: Rodent models of major depressive disorder with peripartum onset - p. page_33 13. Chapter 5: Depression in mothers and mental health in their children: Impact, risk factors, and interventions - p. page_45 14. Chapter 6: The neuroscience of depression: Mechanisms and treatments - p. page_57 15. Chapter 7: Depression in disasters and traumatic events - p. page_69 16. Chapter 8: Depression and associated Alzheimer’s disease - p. page_79 17. Chapter 9: Comorbidities of depression and Parkinson’s disease - p. page_89 18. Chapter 10: Understanding the relationship between depression and alcohol among students - p. page_99 19. Chapter 11: Depression in obesity - p. page_115 20. Chapter 12: Heart rate variability and depression - p. page_121 21. Chapter 13: Neuroinflammation and depression - p. page_131 22. Chapter 14: Interlinking antidepressants and the immune system - p. page_143 23. Part II: Biomarkers and diagnosis - p. page_151 24. Chapter 15: Assessment scoring tools of depression - p. page_155 25. Chapter 16: The Beck depression inventory: Uses and applications - p. page_165 26. Chapter 17: Hamilton depression rating scale: Uses and applications - p. page_175 27. Chapter 18: The patient health questionnaire (PHQ) - p. page_185 28. Chapter 19: Screening for antenatal depression (AND) using self-report questionnaires: Conceptual issues and measurement limitations - p. page_195 29. Chapter 20: Edinburgh postnatal depression scale: Description and applications - p. page_205 30. Chapter 21: The death depression scale: Description and applications - p. page_211 31. Chapter 22: The Depression Anxiety Stress Scale: Features and applications - p. page_219 32. Chapter 23: Arabic version of the two-question quick inventory of depression (QID-2-AR): Description and applications - p. page_229 33. Chapter 24: Depression and biomarkers of cardiovascular disease - p. page_239 34. Chapter 25: Thioredoxin as an antioxidant protein as a marker in depression - p. page_251 35. Chapter 26: Methods of neuroimaging in depression: Applications to resting-state functional connectivity - p. page_261 36. Chapter 27: Neural markers of depression in MRI - p. page_271 37. Part III: Pharmacological treatments for depression - p. page_279 38. Chapter 28: Angiotensin receptor 1 blockade as an antidepression strategy - p. page_283 39. Chapter 29: The link between cannabinoids and depression - p. page_293 40. Chapter 30: Agomelatine: Profile and applications to depression - p. page_301 41. Chapter 31: Bumetanide and use in depressive states - p. page_309 42. Chapter 32: Linking citalopram, serotonin reuptake inhibitors, and depressed pregnant women - p. page_325 43. Chapter 33: Citalopram and its use in sleep-deprivation-induced depression - p. page_337 44. Chapter 34: Monoaminergic system and antidepressants - p. page_345 45. Chapter 35: Duloxetine usage in depression - p. page_357 46. Chapter 36: Escitalopram and blonanserin as antidepressant agents linking in neurotrophic mechanisms - p. page_369 47. Chapter 37: (2R,6R)-Hydroxynorketamine as a novel antidepressant and its role in the antidepressant actions of (R,S)-ketamine - p. page_381 48. Chapter 38: Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model - p. page_393 49. Chapter 39: Mirtazapine: Multitarget strategies for treating substance use disorder and depression - p. page_401 50. Part IV: Counselling, psychotherapy and behavioural treatments for depression - p. page_410 51. Chapter 40: Mindfulness-based cognitive therapy and depression - p. page_413 52. Chapter 41: Online programs for depression - p. page_423 53. Chapter 42: Clay art therapy on emotion regulation: Research, theoretical underpinnings, and treatment mechanisms - p. page_431 54. Chapter 43: Solution-focused counseling and its use in postpartum depression - p. page_443 55. Chapter 44: Transcranial direct current stimulation (tDCS) combined with cognitive emotional training (CET) as a novel treatment for depression - p. page_447 56. Part V: Other aspects of treatment: Specific groups, monitoring and novel regimens - p. page_456 57. Chapter 45: Putative effects of cannabidiol in depression and synaptic plasticity - p. page_459 58. Chapter 46: Transcutaneous auricular vagus nerve stimulation in the treatment of depression - p. page_469 59. Chapter 47: Exercise for depression as a primary and comorbid with obesity disorder: A narrative - p. page_477 60. Chapter 48: Acupressure and depression: A scientific narrative - p. page_487 61. Chapter 49: Potential beneficial effects of Bifidobacterium breve A1 on cognitive impairment and psychiatric disorders - p. page_497 62. Chapter 50: Coenzyme Q10 and depression - p. page_505 63. Chapter 51: Gene expression in major depressive disorder: Peripheral tissue and brain-based studies - p. page_515 64. Chapter 52: Electroconvulsive therapy for depression: Effectiveness, cognitive side-effects, and mechanisms of action - p. page_527 65. Chapter 53: Prenatal depression and offspring DNA methylation - p. page_537 66. Chapter 54: Treating depression with theta burst stimulation (TBS) - p. page_547 67. Index - p. page_553
The Neuroscience of Depression: Features, Diagnosis and Treatment, is a comprehensive reference to the diagnosis and treatment of depression. This book provides readers with the mechanisms of depression reflecting on the interplay between depression and the biological and psychosocial processes. A detailed introduction to various episodes of depression, from PTSD to post-partum depression is provided, followed by a thorough discussion on biomarkers in depression and how to diagnose depression including the Hamilton Depression Rating scale. This book also includes three full sections on treatment options for depression, including pharmacological, behavioral and other novel regimes. The Neuroscience of Depression: Features, Diagnosis and Treatment is the only resource for researchers and practitioners studying, diagnosis and treating of depression.
1. Cover image - p. page_i 2. Title page - p. page_i 3. Table of Contents - p. page_i 4. Copyright - p. page_iv 5. Contributors - p. page_xix 6. Foreword - p. page_xxv 7. Preface - p. page_xxvii 8. Part I: Depression: Introductory chapters - p. page_xxvii 9. Chapter 1: Clinical staging in depression - p. page_3 10. Chapter 2: Neurodevelopmental theory of depression - p. page_13 11. Chapter 3: Depression after pregnancy - p. page_21 12. Chapter 4: Modeling maternal depression during pregnancy: Rodent models of major depressive disorder with peripartum onset - p. page_33 13. Chapter 5: Depression in mothers and mental health in their children: Impact, risk factors, and interventions - p. page_45 14. Chapter 6: The neuroscience of depression: Mechanisms and treatments - p. page_57 15. Chapter 7: Depression in disasters and traumatic events - p. page_69 16. Chapter 8: Depression and associated Alzheimer’s disease - p. page_79 17. Chapter 9: Comorbidities of depression and Parkinson’s disease - p. page_89 18. Chapter 10: Understanding the relationship between depression and alcohol among students - p. page_99 19. Chapter 11: Depression in obesity - p. page_115 20. Chapter 12: Heart rate variability and depression - p. page_121 21. Chapter 13: Neuroinflammation and depression - p. page_131 22. Chapter 14: Interlinking antidepressants and the immune system - p. page_143 23. Part II: Biomarkers and diagnosis - p. page_151 24. Chapter 15: Assessment scoring tools of depression - p. page_155 25. Chapter 16: The Beck depression inventory: Uses and applications - p. page_165 26. Chapter 17: Hamilton depression rating scale: Uses and applications - p. page_175 27. Chapter 18: The patient health questionnaire (PHQ) - p. page_185 28. Chapter 19: Screening for antenatal depression (AND) using self-report questionnaires: Conceptual issues and measurement limitations - p. page_195 29. Chapter 20: Edinburgh postnatal depression scale: Description and applications - p. page_205 30. Chapter 21: The death depression scale: Description and applications - p. page_211 31. Chapter 22: The Depression Anxiety Stress Scale: Features and applications - p. page_219 32. Chapter 23: Arabic version of the two-question quick inventory of depression (QID-2-AR): Description and applications - p. page_229 33. Chapter 24: Depression and biomarkers of cardiovascular disease - p. page_239 34. Chapter 25: Thioredoxin as an antioxidant protein as a marker in depression - p. page_251 35. Chapter 26: Methods of neuroimaging in depression: Applications to resting-state functional connectivity - p. page_261 36. Chapter 27: Neural markers of depression in MRI - p. page_271 37. Part III: Pharmacological treatments for depression - p. page_279 38. Chapter 28: Angiotensin receptor 1 blockade as an antidepression strategy - p. page_283 39. Chapter 29: The link between cannabinoids and depression - p. page_293 40. Chapter 30: Agomelatine: Profile and applications to depression - p. page_301 41. Chapter 31: Bumetanide and use in depressive states - p. page_309 42. Chapter 32: Linking citalopram, serotonin reuptake inhibitors, and depressed pregnant women - p. page_325 43. Chapter 33: Citalopram and its use in sleep-deprivation-induced depression - p. page_337 44. Chapter 34: Monoaminergic system and antidepressants - p. page_345 45. Chapter 35: Duloxetine usage in depression - p. page_357 46. Chapter 36: Escitalopram and blonanserin as antidepressant agents linking in neurotrophic mechanisms - p. page_369 47. Chapter 37: (2R,6R)-Hydroxynorketamine as a novel antidepressant and its role in the antidepressant actions of (R,S)-ketamine - p. page_381 48. Chapter 38: Linking 5-hydroxytryptamine to antidepressant actions of (R)-ketamine and social stress model - p. page_393 49. Chapter 39: Mirtazapine: Multitarget strategies for treating substance use disorder and depression - p. page_401 50. Part IV: Counselling, psychotherapy and behavioural treatments for depression - p. page_410 51. Chapter 40: Mindfulness-based cognitive therapy and depression - p. page_413 52. Chapter 41: Online programs for depression - p. page_423 53. Chapter 42: Clay art therapy on emotion regulation: Research, theoretical underpinnings, and treatment mechanisms - p. page_431 54. Chapter 43: Solution-focused counseling and its use in postpartum depression - p. page_443 55. Chapter 44: Transcranial direct current stimulation (tDCS) combined with cognitive emotional training (CET) as a novel treatment for depression - p. page_447 56. Part V: Other aspects of treatment: Specific groups, monitoring and novel regimens - p. page_456 57. Chapter 45: Putative effects of cannabidiol in depression and synaptic plasticity - p. page_459 58. Chapter 46: Transcutaneous auricular vagus nerve stimulation in the treatment of depression - p. page_469 59. Chapter 47: Exercise for depression as a primary and comorbid with obesity disorder: A narrative - p. page_477 60. Chapter 48: Acupressure and depression: A scientific narrative - p. page_487 61. Chapter 49: Potential beneficial effects of Bifidobacterium breve A1 on cognitive impairment and psychiatric disorders - p. page_497 62. Chapter 50: Coenzyme Q10 and depression - p. page_505 63. Chapter 51: Gene expression in major depressive disorder: Peripheral tissue and brain-based studies - p. page_515 64. Chapter 52: Electroconvulsive therapy for depression: Effectiveness, cognitive side-effects, and mechanisms of action - p. page_527 65. Chapter 53: Prenatal depression and offspring DNA methylation - p. page_537 66. Chapter 54: Treating depression with theta burst stimulation (TBS) - p. page_547 67. Index - p. page_553
